PMID: 6767639Jan 1, 1980Paper

Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide

Diabetologia
G SartorE Wåhlin-Boll

Abstract

The steady state concentrations of glibenclamide in serum were measured radioimmunologically in 37 diabetic patients after administration for at least a year. No other antidiabetic drugs had been given. The interindividual variation in glibenclamide concentrations was extremely large (0 to 1520 nmol/l), greatly exceeding the variation in dosage (2.5--25 mg daily). There was no relation between dose and serum concentration of glibenclamide. Only four (9%) patients had fasting blood glucose concentrations below 5.5 mmol/l, and fewer than half had values below 8 mmol/l. In most cases, therefore, the therapy was inadequate. Single-dose kinetics of glibenclamide was assessed in healthy volunteers. Food intake did not influence the bioavailability of a 5 mg dose of glibenclamide. There was no insulin increase in response to glibenclamide unless a meal was also given, and this increase was not significant until 1 h after administration of drug and meal, when the mean serum concentration of glibenclamide had reached 100 nmol/l. Even in the fasting state, however, there was a progressive fall in blood glucose after glibenclamide administration, significant within 45 min and with a nadir at 2--2 1/2 h.

References

Jan 1, 1976·Clinical Pharmacokinetics·G Johnsson, C G Regàrdh
Sep 1, 1978·Clinical Pharmacokinetics·A Melander
Mar 3, 1977·The New England Journal of Medicine·S W Shen, R Bressler
Apr 7, 1977·The New England Journal of Medicine·S W Shen, R Bressler
Jan 21, 1978·British Medical Journal·A MelanderP O Bitzén
Mar 4, 1978·British Medical Journal·F N Eshelman
Apr 15, 1978·British Medical Journal·A Melander
Mar 1, 1969·Archives of Internal Medicine·J M Feldman, H E Lebovitz
Jul 1, 1966·Journal of Medicinal Chemistry·R C Thomas, G J Ikeda
Jan 1, 1982·European Journal of Clinical Pharmacology·E Wåhlin-BollB Scherstén

Citations

Jan 1, 1982·European Journal of Clinical Pharmacology·G SartorE Wåhlin-Boll
Jan 1, 1982·European Journal of Clinical Pharmacology·E J AntalK S Albert
Oct 1, 1980·European Journal of Clinical Pharmacology·E Wåhlin-BollB Scherstén
Jan 1, 1982·European Journal of Clinical Pharmacology·E Wåhlin-BollB Scherstén
Apr 1, 1980·European Journal of Clinical Pharmacology·G SartorE Wåhlin-Boll
Jun 12, 2008·European Journal of Drug Metabolism and Pharmacokinetics·M T Bakare-OdunolaI Abdu Aguye
Aug 30, 1984·Biochemical and Biophysical Research Communications·C K Buffington, A E Kitabchi
Jun 1, 1990·British Journal of Clinical Pharmacology·S W CoppackA V Rodgers
Aug 1, 1990·British Journal of Clinical Pharmacology·D HartmannW K Waldhäusl
Sep 1, 1990·British Journal of Clinical Pharmacology·M L Dahl-PuustinenI Wikström
Mar 1, 1984·Acta Physiologica Scandinavica·L Norlund, J Sehlin
May 25, 2013·Science·Hirohito HarukiKai Johnsson
Jul 3, 2013·Obstetrics and Gynecology·Steve N Caritis, Mary F Hebert
Feb 28, 2001·Diabetes, Obesity & Metabolism·L G Howes
Dec 1, 1989·Chest·T H SelfJ W Fowler
Oct 25, 2006·Clinical and Experimental Hypertension : CHE·Matthias HuberReinhold Kreutz
Mar 13, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·W W Yew
Jan 26, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·M YngenN H Wallén
Feb 24, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·U M MortensenTorsten Toftegaard Nielsen
May 4, 2010·Biopharmaceutics & Drug Disposition·Lin ZhouQingcheng Mao
Sep 20, 1985·The American Journal of Medicine·J M Feldman
Jun 1, 2015·Journal of Pharmacological and Toxicological Methods·Rob WallisHelen Maddock
Feb 1, 1981·The American Journal of Medicine·T G Skillman, J M Feldman
Aug 5, 2015·Obstetrics and Gynecology·Roxanna TwedtFrancesca Facco
Jan 1, 1985·The Diabetes Educator·D E Baker, R K Campbell
Jan 1, 1992·European Journal of Clinical Pharmacology·W WörnerN Rietbrock
May 30, 2019·Acta Neurologica Scandinavica·Kaibin HuangSuyue Pan
Jul 26, 2019·Angewandte Chemie·Lieby ZborovskyYitzhak Apeloig
Dec 1, 1987·Journal of Endocrinological Investigation·K G MountjoyI M Holdaway
Jan 1, 1980·Acta Medica Scandinavica·G SartorE Wåhlin-Boll
Jan 1, 1981·Acta Medica Scandinavica. Supplementum·A MelanderE Wåhlin-Boll
Oct 10, 2003·Scandinavian Cardiovascular Journal : SCJ·Ulrik Markus MortensenTorsten Toftegaard Nielsen
Jul 4, 2020·Journal of Pharmacological and Toxicological Methods·Yoshiko OkaiTadahiro Shinozawa
Mar 1, 1985·The American Journal of Physiology·B DrazninK E Sussman
Sep 27, 2000·Journal of Diabetes and Its Complications·F M Ashcroft, F M Gribble

Related Concepts

Blood Glucose
Diabetes Mellitus
Dose-Response Relationship, Drug
Ingestion
Neogluconin
Insulin B Chain

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Laryngeal Neoplasms

Laryngeal Neoplasms occur in the Larynx and are typically associated with smoking and alcohol consumption. Discover the latest research on Laryngeal Neoplasms here.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.